Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications

Dimitrios Kouroupis, Clara Sanjurjo-Rodriguez, Elena Jones, Diego Correa

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in various clinical trials with moderate or, in some cases, inconsistent results. The still elusive reproducibility relates, in part, with constitutive differences in the cell preparation, translated into variable cell potencies. Other factors include poor cell homing and survival, and age-/disease-associated host tissue impairment. It is well accepted that within in vivo niches, MSCs exist as heterogeneous cell populations with different stemness propensities and supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization in vitro, through cell priming, can boost their immunomodulatory, trophic, and reparative capacities in vivo. Therefore, in this review, we discuss how phenotype-based MSC purification and MSC priming technologies can contribute to an improved MSC-based product for safer and more effective therapeutic applications. Culture expansion of MSCs has detrimental effects on various cell characteristics and attributes (e.g., phenotypic changes and senescence), which, in addition to inherent interdonor variability, negatively impact the standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional MSC subpopulations, as well as the description of ex vivo protocols aimed at maintaining phenotypes and enhancing specific functions have the potential to overcome these limitations. The incorporation of those approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes may be achieved.

Original languageEnglish (US)
Pages (from-to)55-77
Number of pages23
JournalTissue Engineering - Part B: Reviews
Volume25
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Purification
Cells
Set theory
Phenotype
Standardization
Therapeutics
Tissue
Cell- and Tissue-Based Therapy
Population
Cell Survival
Clinical Trials
Technology

Keywords

  • cell priming
  • cellular phenotypes
  • mesenchymal stem cells
  • MSC subpopulations

ASJC Scopus subject areas

  • Bioengineering
  • Biomaterials
  • Biochemistry
  • Biomedical Engineering

Cite this

Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications. / Kouroupis, Dimitrios; Sanjurjo-Rodriguez, Clara; Jones, Elena; Correa, Diego.

In: Tissue Engineering - Part B: Reviews, Vol. 25, No. 1, 01.02.2019, p. 55-77.

Research output: Contribution to journalReview article

Kouroupis, Dimitrios ; Sanjurjo-Rodriguez, Clara ; Jones, Elena ; Correa, Diego. / Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications. In: Tissue Engineering - Part B: Reviews. 2019 ; Vol. 25, No. 1. pp. 55-77.
@article{712ae2f74b1e4cdea1a3f225a6359bef,
title = "Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications",
abstract = "To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in various clinical trials with moderate or, in some cases, inconsistent results. The still elusive reproducibility relates, in part, with constitutive differences in the cell preparation, translated into variable cell potencies. Other factors include poor cell homing and survival, and age-/disease-associated host tissue impairment. It is well accepted that within in vivo niches, MSCs exist as heterogeneous cell populations with different stemness propensities and supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization in vitro, through cell priming, can boost their immunomodulatory, trophic, and reparative capacities in vivo. Therefore, in this review, we discuss how phenotype-based MSC purification and MSC priming technologies can contribute to an improved MSC-based product for safer and more effective therapeutic applications. Culture expansion of MSCs has detrimental effects on various cell characteristics and attributes (e.g., phenotypic changes and senescence), which, in addition to inherent interdonor variability, negatively impact the standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional MSC subpopulations, as well as the description of ex vivo protocols aimed at maintaining phenotypes and enhancing specific functions have the potential to overcome these limitations. The incorporation of those approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes may be achieved.",
keywords = "cell priming, cellular phenotypes, mesenchymal stem cells, MSC subpopulations",
author = "Dimitrios Kouroupis and Clara Sanjurjo-Rodriguez and Elena Jones and Diego Correa",
year = "2019",
month = "2",
day = "1",
doi = "10.1089/ten.teb.2018.0118",
language = "English (US)",
volume = "25",
pages = "55--77",
journal = "Tissue Engineering - Part B: Reviews",
issn = "1937-3368",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications

AU - Kouroupis, Dimitrios

AU - Sanjurjo-Rodriguez, Clara

AU - Jones, Elena

AU - Correa, Diego

PY - 2019/2/1

Y1 - 2019/2/1

N2 - To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in various clinical trials with moderate or, in some cases, inconsistent results. The still elusive reproducibility relates, in part, with constitutive differences in the cell preparation, translated into variable cell potencies. Other factors include poor cell homing and survival, and age-/disease-associated host tissue impairment. It is well accepted that within in vivo niches, MSCs exist as heterogeneous cell populations with different stemness propensities and supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization in vitro, through cell priming, can boost their immunomodulatory, trophic, and reparative capacities in vivo. Therefore, in this review, we discuss how phenotype-based MSC purification and MSC priming technologies can contribute to an improved MSC-based product for safer and more effective therapeutic applications. Culture expansion of MSCs has detrimental effects on various cell characteristics and attributes (e.g., phenotypic changes and senescence), which, in addition to inherent interdonor variability, negatively impact the standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional MSC subpopulations, as well as the description of ex vivo protocols aimed at maintaining phenotypes and enhancing specific functions have the potential to overcome these limitations. The incorporation of those approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes may be achieved.

AB - To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in various clinical trials with moderate or, in some cases, inconsistent results. The still elusive reproducibility relates, in part, with constitutive differences in the cell preparation, translated into variable cell potencies. Other factors include poor cell homing and survival, and age-/disease-associated host tissue impairment. It is well accepted that within in vivo niches, MSCs exist as heterogeneous cell populations with different stemness propensities and supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization in vitro, through cell priming, can boost their immunomodulatory, trophic, and reparative capacities in vivo. Therefore, in this review, we discuss how phenotype-based MSC purification and MSC priming technologies can contribute to an improved MSC-based product for safer and more effective therapeutic applications. Culture expansion of MSCs has detrimental effects on various cell characteristics and attributes (e.g., phenotypic changes and senescence), which, in addition to inherent interdonor variability, negatively impact the standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional MSC subpopulations, as well as the description of ex vivo protocols aimed at maintaining phenotypes and enhancing specific functions have the potential to overcome these limitations. The incorporation of those approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes may be achieved.

KW - cell priming

KW - cellular phenotypes

KW - mesenchymal stem cells

KW - MSC subpopulations

UR - http://www.scopus.com/inward/record.url?scp=85061562416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061562416&partnerID=8YFLogxK

U2 - 10.1089/ten.teb.2018.0118

DO - 10.1089/ten.teb.2018.0118

M3 - Review article

C2 - 30165783

AN - SCOPUS:85061562416

VL - 25

SP - 55

EP - 77

JO - Tissue Engineering - Part B: Reviews

JF - Tissue Engineering - Part B: Reviews

SN - 1937-3368

IS - 1

ER -